Voloridge Investment Management LLC lowered its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 36.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 491,927 shares of the medical technology company's stock after selling 286,391 shares during the quarter. Voloridge Investment Management LLC owned 0.35% of Alphatec worth $4,516,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of ATEC. Royal Bank of Canada grew its holdings in Alphatec by 171.2% during the fourth quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock worth $29,240,000 after buying an additional 2,010,806 shares in the last quarter. American Century Companies Inc. grew its holdings in Alphatec by 36.5% during the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after buying an additional 1,334,780 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Alphatec by 78.4% in the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock valued at $23,730,000 after purchasing an additional 1,136,330 shares during the period. Marshall Wace LLP grew its stake in Alphatec by 139.2% in the 4th quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock valued at $16,278,000 after purchasing an additional 1,032,070 shares during the period. Finally, Emerald Advisers LLC grew its stake in Alphatec by 112.4% in the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock valued at $13,366,000 after purchasing an additional 770,586 shares during the period. Institutional investors own 66.35% of the company's stock.
Alphatec Price Performance
Shares of NASDAQ ATEC traded down $0.04 during trading hours on Friday, reaching $12.42. 1,784,042 shares of the stock traded hands, compared to its average volume of 2,047,763. The company has a market capitalization of $1.82 billion, a P/E ratio of -9.70 and a beta of 1.06. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.14. The company's 50-day simple moving average is $11.29 and its two-hundred day simple moving average is $10.64.
Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $169.18 million for the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. The company's revenue for the quarter was up 22.2% compared to the same quarter last year. Equities research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on ATEC. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a research note on Monday, April 14th. Wall Street Zen upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Piper Sandler reiterated an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.89.
Check Out Our Latest Analysis on ATEC
Insider Buying and Selling at Alphatec
In other news, EVP David Sponsel sold 33,732 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at approximately $7,245,020.91. This represents a 4.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Scott Lish sold 12,000 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $12.12, for a total value of $145,440.00. Following the completion of the sale, the chief operating officer now owns 826,251 shares in the company, valued at approximately $10,014,162.12. The trade was a 1.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 113,798 shares of company stock valued at $1,365,665. Company insiders own 20.90% of the company's stock.
About Alphatec
(
Free Report)
Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.
Read More
Before you consider Alphatec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.
While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
